Insider Selling: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells $130,635.75 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Ellen Chiniara sold 3,129 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total value of $130,635.75. Following the transaction, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $40.52 on Thursday. The company has a market capitalization of $2.62 billion, a price-to-earnings ratio of -17.32 and a beta of 2.19. The stock has a 50-day moving average of $44.20 and a 200 day moving average of $43.92. Kymera Therapeutics, Inc. has a one year low of $25.46 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same period in the previous year, the company earned ($0.90) earnings per share. The firm’s quarterly revenue was down 20.9% on a year-over-year basis. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Values First Advisors Inc. bought a new stake in shares of Kymera Therapeutics in the third quarter worth $61,000. Quarry LP purchased a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at about $95,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after purchasing an additional 504 shares during the period. Public Employees Retirement Association of Colorado purchased a new position in shares of Kymera Therapeutics in the second quarter worth approximately $139,000. Finally, Quest Partners LLC grew its position in Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after buying an additional 4,865 shares during the period.

Wall Street Analyst Weigh In

KYMR has been the subject of several research reports. Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. UBS Group decreased their price target on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Truist Financial reaffirmed a “buy” rating and set a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Guggenheim boosted their price target on Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $55.38.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.